Nom du produit:Benzo[d]thiazole-6-sulfonyl chloride
IUPAC Name:1,3-benzothiazole-6-sulfonyl chloride
- CAS:181124-40-3
- Formule moléculaire:C7H4ClNO2S2
- Pureté:97%
- Numéro de catalogue:CM158498
- Poids moléculaire:233.68
Pour une utilisation en R&D uniquement..
Détails du produit
- N° CAS:181124-40-3
- Formule moléculaire:C7H4ClNO2S2
- Point de fusion:-
- Code SMILES:O=S(C1=CC=C2N=CSC2=C1)(Cl)=O
- Densité:
- Numéro de catalogue:CM158498
- Poids moléculaire:233.68
- Point d'ébullition:376.9°C at 760 mmHg
- N° Mdl:
- Stockage:Store in freezer, under -20°C.
Category Infos
- Benzothiazoles
- Benzothiazoles are aromatic heterocyclic compounds with the chemical formula C7H5NS. Benzothiazoles and their derivatives are a very important class of heterocyclic compounds that are ubiquitous in nature and are mainly used in medicine, agriculture and industry. In medicine, benzothiazole derivatives are a kind of very important pharmaceutical intermediates with good pharmacological and biological activities. It can be used as a fungicide, anti-tuberculosis drug, anti-malarial, anti-convulsant, insecticide, sedative and anti-inflammatory drug, and can also be used to treat diabetes and has anti-cancer effects.
Column Infos
- Lanifibranor
- Recently, Inventiva announced positive results of its interim analysis of the Phase II, Proof-of-Concept clinical trial, LEGEND, evaluating lanifibranor in combination with empagliflozin in patients with MASH/NASH and poorly controlled Type 2 Diabetes (T2D). The study achieved the primary efficacy endpoint. Lanifibranor is an orally-available small molecule pan PPAR agonist with a -wellbalanced- activation of PPARα and PPARδ, and a partial activation of PPARγ. Lanifibranor acts to induce anti fibrotic, anti-inflammatory and beneficial vascular and metabolic changes in the body.